Hydroxychloroquine has made frequent appearances in national headlines throughout the pandemic as the medical community and federal government struggled to establish a cohesive opinion on the drug’s effectiveness in treating COVID-19.
The CDC report revealed that more than 1.3 million prescriptions were written for hydroxychloroquine in March and April, compared to nearly 820,000 during the same period in 2019.
The report also revealed that nonroutine prescribers — personnel who are not primary care doctors who would usually prescribe the drug — wrote more than 75,000 prescriptions for hydroxychloroquine or chloroquine, its sister drug, in March. That accounts for a 6,511 percent increase in hydroxychloroquine and chloroquine prescriptions written by that group from February.
The nonroutine prescribing specialties with the largest hydroxychloroquine prescription volume increase in March were ophthalmology, anesthesiology and cardiology, according to the agency.
More articles on pharmacy:
2nd FDA appointee ousted as agency faces criticism from medical community
Eli Lilly stops giving 340B discounts to contract pharmacies
5 requests biotech CEOs have for their peers, the FDA regarding COVID-19 vaccine development
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
